{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:59:14Z","timestamp":1793757554697,"version":"4.6.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Sabin Family Foundation"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Differential censoring, which refers to censoring imbalance between treatment arms, may bias the interpretation of survival outcomes in clinical trials. In 146 phase III oncology trials with statistically significant time-to-event surrogate primary endpoints, we evaluated the association between differential censoring in the surrogate primary endpoints, control arm adequacy, and the subsequent statistical significance of overall survival results. Twenty-four (16%) trials exhibited differential censoring that favored the control arm, whereas 15 (10%) exhibited differential censoring that favored the experimental arm. Positive overall survival was more common in control arm differential censoring trials (63%) than in trials without differential censoring (37%) or with experimental arm differential censoring (47%; odds ratio\u2009=\u20092.64, 95% confidence interval\u2009=\u20091.10 to 7.20; P\u2009=\u2009.04). Control arm differential censoring trials more frequently used suboptimal control arms at 46% compared with 20% without differential censoring and 13% with experimental arm differential censoring (odds ratio\u2009=\u20093.60, 95% confidence interval\u2009=\u20091.29 to 10.0; P\u2009=\u2009.007). The presence of control arm differential censoring in trials with surrogate primary endpoints, especially in those with overall survival conversion, may indicate an inadequate control arm and should be examined and explained.<\/jats:p>","DOI":"10.1093\/jnci\/djae028","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:18:38Z","timestamp":1707437918000},"page":"990-994","source":"Crossref","is-referenced-by-count":12,"title":["Association of differential censoring with survival and suboptimal control arms among oncology clinical trials"],"prefix":"10.1093","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6743-2399","authenticated-orcid":false,"given":"Eric J","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center , Dallas, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]},{"name":"Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dor R","family":"Dabush","sequence":"additional","affiliation":[{"name":"Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"McCaw","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of North Carolina at Chapel Hill , Chapel Hill, NC,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Koong","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Abi Jaoude","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshal","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez","family":"Kouzy","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly B","family":"El Alam","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Noticewala","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Bioinformatics, University of Texas Health Science Center at Houston , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D","family":"Sherry","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton D","family":"Fuller","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Charles R","family":"Thomas","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Dartmouth Cancer Center, Geisel School of Medicine , Lebanon, NH,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajnan","family":"Das","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Huang","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Groton, CT,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5893-0169","authenticated-orcid":false,"given":"Lu","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Health Research and Policy, Stanford University , Stanford, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-1561","authenticated-orcid":false,"given":"Ryan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Jack","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-5477","authenticated-orcid":false,"given":"Tomer","family":"Meirson","sequence":"additional","affiliation":[{"name":"Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva,","place":["Israel"]},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5472-5344","authenticated-orcid":false,"given":"Ethan B","family":"Ludmir","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]},{"name":"Department of Biostatistics, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"issue":"6","key":"2025062416150395000_djae028-B1","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/ANNONC\/MDR492","article-title":"Randomized controlled trials in the era of molecular oncology: Methodology, biomarkers, and end points","volume":"23","author":"Kay","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"2025062416150395000_djae028-B2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/BIMJ.201400049","article-title":"Statistical evaluation of surrogate endpoints with examples from cancer clinical trials","volume":"58","author":"Buyse","year":"2016","journal-title":"Biom J"},{"issue":"6","key":"2025062416150395000_djae028-B3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/J.MAYOCP.2016.02.012","article-title":"Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration\u2019s Approval of Oncology Drugs","volume":"91","author":"Kim","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2025062416150395000_djae028-B4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/J.EJCA.2020.06.015","article-title":"Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials","volume":"136","author":"Pasalic","year":"2020","journal-title":"Eur J Cancer"},{"issue":"8","key":"2025062416150395000_djae028-B5","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/JAMAINTERNMED.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"17","key":"2025062416150395000_djae028-B6","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1200\/JClinOncol.2008.20.4107","article-title":"Issues in using progression-free survival when evaluating oncology products","volume":"27","author":"Fleming","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025062416150395000_djae028-B7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/10543406.2013.813515","article-title":"Missing data and censoring in the analysis of progression-free survival in oncology clinical trials","volume":"23","author":"Denne","year":"2013","journal-title":"J Biopharm Stat"},{"issue":"6","key":"2025062416150395000_djae028-B8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/S41571-020-0368-0","article-title":"Informative censoring\u2014a neglected cause of bias in oncology trials","volume":"17","author":"Templeton","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025062416150395000_djae028-B9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/J.EJCA.2021.04.044","article-title":"Informative censoring of surrogate end-point data in phase 3 oncology trials","volume":"153","author":"Gilboa","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10","key":"2025062416150395000_djae028-B10","doi-asserted-by":"publisher","first-page":"e2017675","DOI":"10.1001\/JAMANETWORKOPEN.2020.17675","article-title":"Survival-inferred fragility index of phase 3 clinical trials evaluating immune checkpoint inhibitors","volume":"3","author":"Meirson","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2025062416150395000_djae028-B11","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1001\/JAMAONCOL.2019.2055","article-title":"Factors associated with age disparities among cancer clinical trial participants","volume":"5","author":"Ludmir","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"2025062416150395000_djae028-B12","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/JAMAONCOL.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US food and drug administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"2025062416150395000_djae028-B13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/JAMAINTERNMED.2020.2250","article-title":"Limitations in clinical trials leading to anticancer drug approvals by the us food and drug administration","volume":"180","author":"Hilal","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2025062416150395000_djae028-B14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"19","key":"2025062416150395000_djae028-B15","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMOA1510016\/SUPPL_FILE\/NEJMOA1510016_DISCLOSURES.PDF","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"New Engl J Med"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djae028\/56776923\/djae028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/116\/6\/990\/58166252\/djae028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/116\/6\/990\/58166252\/djae028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T20:15:06Z","timestamp":1750796106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/116\/6\/990\/7603054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,2,9]]},"published-print":{"date-parts":[[2024,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djae028","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,2,9]]}}}